Results 71 to 80 of about 1,013 (109)

First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN

, 2021
Background: Lorlatinib, a 3rd-generation ALK inhibitor, significantly prolonged progression-free survival (PFS) vs crizotinib in the CROWN trial in patients with untreated ALK-positive non-small cell lung cancer (NSCLC).
Chiu, CH, Kim, DW, Mok, T, Hayashi, H, Lin, CC, Teraoka, S, Lee, VHF, Chang, GC, Calella, AM, Lu, S, Zhou, Q, Kim, SW, Goto, Y, Zhou, J, Kim, HR, Soo, R, Polli, A, Han, B, Ho, JCM, Wu, YL   +19 more
core   +1 more source

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c‐ros Oncogene 1 (ROS1)‐Positive Non–Small Cell Lung Cancer (NSCLC), a Multicenter Real‐World Study

MedComm, Volume 7, Issue 7, July 2026.
This large real‐world study confirms crizotinib's intracranial benefit and underscores the importance of next‐generation ROS1 inhibitors and older‐generation agents like lorlatinib—for improved patient outcomes after crizotinib resistance. ABSTRACT Intracranial efficacy of crizotinib and optimal postprogression therapies in c‐ros oncogene 1 (ROS1 ...
Zihua Zou, Xiaobin Zheng, Panwen Tian, Zhe Liu, Jie Hu, Yong Fang, Yang Xia, Feng Ye, Tangfeng Lv, Li Li, Diansheng Zhong, Jin Zhou, Qian Chu, Meiqi Shi, Chengbo Han, Baoshan Cao, Dingzhi Huang, Hui Guo, Gen Lin   +18 more
wiley   +1 more source

CRISPR‐Cas9 Genome‐Wide Screening in Paediatric Cancer: Functional Genomics for Target Discovery and the Improvement of Existing Therapies

Medicinal Research Reviews, Volume 46, Issue 4, Page 989-1004, July 2026.
ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He, Patrick Connerty, Antoine de Weck   +2 more
wiley   +1 more source

Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib

, 2017
Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer. They are currently treated with the first-generation ALK inhibitor crizotnib followed by more potent, second-generation ALK inhibitors, such ...
Satoshi Yoda, Alice T. Shaw, Leila Dardaei, Manrose Singh, Jeffrey A. Engelman, Aaron N. Hata   +5 more
core   +1 more source

Inhibition of ROS1 activity with lorlatinib reversibly suppresses fertility in male mice [PDF]

Oyama Y., Shimada K., Miyata H., et al. Inhibition of ROS1 activity with lorlatinib reversibly suppresses fertility in male mice. Andrology , (2024); https://doi.org/10.1111/andr.13808.Background: Inhibition of sperm maturation in the epididymis is a ...
Miyata, Haruhiko, Ikawa, Masahito, Matzuk, Martin M., Shimada, Kentaro, Kamoshita, Maki, Emori, Chihiro, Oura, Seiya, Iida-Norita, Rie, Katayama, Ryohei, Oyama, Yuki   +9 more
core   +2 more sources

Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK‐Positive Lung Adenocarcinoma: A Case Report

Respirology Case Reports, Volume 14, Issue 7, July 2026.
We report a case of ALK‐positive NSCLC in which lorlatinib was successfully administered after discontinuation of alectinib due to drug eruption. Switching to another ALK inhibitor with a distinct chemical structure and safety profile may represent a practical therapeutic option when hypersensitivity reactions prevent continuation of alectinib. Further
Shunsuke Omura, Keeya Sunata, Tetsuo Tani, Koyuru Uchibori, Shun Shinomiya, Saeko Takahashi   +5 more
wiley   +1 more source

Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib [PDF]

, 2019
Lorlatinib, a novel generation oral anaplastic lymphoma kinase (ALK) and ROS1 inhibitor with high membrane and blood-brain barrier permeability, recently received accelerated approval for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC ...
Afd Chemical Biology and Drug Discovery, Lebre, Maria C., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Wang, Yaogeng, Beijnen, Jos H., Sparidans, Rolf W., Li, Wenlong, Schinkel, Alfred H.   +8 more
core   +1 more source

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

Frontiers in Public Health
BackgroundThe ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients.
Wenjie Liu, Wenjie Liu, Wenjie Liu, Wenjie Liu, Gengwei Huo, Gengwei Huo, Gengwei Huo, Gengwei Huo, Peng Chen, Peng Chen, Peng Chen, Peng Chen   +11 more
doaj   +1 more source

Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry

Journal of Analytical Methods in Chemistry, 2019
In the present study, we developed and validated a rapid and simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of lorlatinib in mouse serum and tissue samples, and such a method was successfully applied to ...
Wei Chen, Yafei Shi, Shuya Qi, Haiyan Zhou, Chunyu Li, Dujia Jin, Guohui Li   +6 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source